Gsk (GSK) Profit After Tax (2009 - 2026)
Gsk (GSK) recorded quarterly Profit After Tax of $2.5 billion in Q1 2026, up 156.38% quarter-over-quarter from $967.0 million in Q4 2025, and up 11.09% on a YoY basis from $2.2 billion in Q1 2025.
Gsk (GSK) Profit After Tax (2009 - 2026) Analysis & Trends
Gsk's Profit After Tax history runs 18 years deep, the most recent figure standing at $2.5 billion for Q1 2026.
- In Q1 2026, Profit After Tax rose 11.09% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $10.0 billion (up 33.55% YoY), while the FY2025 annual figure was $8.3 billion, up 119.82% from the prior year.
- Profit After Tax was $2.5 billion for Q1 2026 at Gsk, up from $967.0 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $4.2 billion in Q4 2023 to a low of $81.9 million in Q3 2024.
- Historically, Profit After Tax has averaged $2.1 billion across 5 years, with a median of $2.2 billion in 2023.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax slumped 95.79% in 2024, then surged 4462.94% in 2025.
- A 5-year view of Profit After Tax shows it stood at $3.0 billion in 2022, then surged by 41.93% to $4.2 billion in 2023, then declined by 26.94% to $3.1 billion in 2024, then sank by 68.41% to $967.0 million in 2025, then soared by 156.38% to $2.5 billion in 2026.
- The last three Profit After Tax figures came in at $2.5 billion (Q1 2026), $967.0 million (Q4 2025), and $3.7 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 2.48 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -4.24 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.48 Bn |
| Dec 31, 2025 | 967.03 Mn |
| Sep 30, 2025 | 3.74 Bn |
| Jun 30, 2025 | 2.84 Bn |
| Mar 31, 2025 | 2.23 Bn |
| Dec 31, 2024 | 3.06 Bn |
| Sep 30, 2024 | 81.86 Mn |
| Jun 30, 2024 | 2.13 Bn |
| Mar 31, 2024 | 1.37 Bn |
| Dec 31, 2023 | 4.19 Bn |
| Sep 30, 2023 | 1.94 Bn |
| Jun 30, 2023 | 2.18 Bn |
| Mar 31, 2023 | 1.98 Bn |
| Dec 31, 2022 | 2.95 Bn |
| Sep 30, 2022 | 918.09 Mn |
| Jun 30, 2022 | 939.45 Mn |
| Mar 31, 2022 | 2.38 Bn |
| Dec 31, 2021 | 566.16 Mn |
| Sep 30, 2021 | 1.30 Bn |
| Jun 30, 2021 | 1.78 Bn |